- Companies
- Tropic Biosciences
Tropic Biosciences Valuation, Funding & Investors
Tropic Biosciences is valued at $967M as of June 2020.
Last Tropic Biosciences valuation
$967M
Series B · Jun 2020
Last Tropic Biosciences funding round
$105M
Series C · Mar 2026
Cumulative funding Tropic Biosciences raised
$179M
across 4 funding rounds
Key investors in Tropic Biosciences
Five Seasons Ventures
Aliment Capital
Tekfen Ventures
Temasek
Future Planet Capital
UK Innovation & Science Seed Fund
About Tropic Biosciences
Tropic Biosciences is an Oxford-based agritech company that develops high-performing commercial varieties of tropical crops using non-GMO gene editing techniques. Its varieties promote grower wellbeing, consumer health, and sustainable environmental practices. The firm targets crops such as bananas and coffee to deliver improved yields and resilience without genetic modification concerns.
Founded
2016
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$967M (Jun 2020)
Sectors
Tropic Biosciences Valuation
Tropic Biosciences is currently valued at $967M, based on its Series B in June 2020.
The $29M round was led by Temasek, with participation from Tekfen Ventures, Skyviews Life Science, Future Planet Capital, Genoa Ventures, Emerald Technology Ventures and 6 other investors.
Tropic Biosciences valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jun 2020 | Series B | $967M |
Tropic Biosciences Funding History
Tropic Biosciences has raised a total of $179M across 4 funding rounds.
Tropic Biosciences' first fundraising round was a $10M Series A in June 2018. The most recent completed round was a $105M Series C in March 2026.
Tropic Biosciences funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Mar 2026 | Series C | Corteva Catalyst (lead); Forbion Capital Partners (lead); Temasek; Polaris Partners; Genoa Ventures; Sucden Ventures; Aliment Capital; IQ Capital; Invest International; Five Seasons Ventures; Just Climate; ABN AMRO Bank | $105M | - | - |
| Jul 2022 | Series C | Blue Horizon Corporation (lead); ADQ; Tekfen Ventures; Skyviews Life Science; Sucden Ventures; Rage Capital; Bloom8; DisruptAD | $35M | - | Tropic Biosciences is a UK-based agricultural biotechnology company developing high-performance varieties of tropical crops like banana, coffee, and rice using proprietary gene-editing technologies such as GEiGS to address climate challenges and promote sustainable practices. The company raised $35 million in a funding round announced on July 6, 2022, led by Blue Horizon with participation from DisruptAD (ADQ’s venture platform), Skyviews Life Science, Bloom8 (fka Rage Capital), Tekfen Ventures, and Sucden Ventures. This bridge round followed a $28.5 million Series B in June 2020 led by Temasek, bringing total funding to over $73 million across multiple rounds since 2016. The proceeds will accelerate commercialization and expansion into new tropical crops, targeting markets estimated at over $400 billion for banana, coffee, and rice that impact more than half a billion people. CEO Gilad Gershon noted the company remained well-funded from the prior Series B but sought this investment to expedite bringing novel products to market and tackle grower challenges. Blue Horizon CEO Björn Witte highlighted Tropic's potential for massive positive impact at scale in sustainable food systems. Tropic has attracted impact and agtech investors including Temasek, Sumitomo Corporation Europe, Genoa Ventures, Agronomics, and UK Innovation & Sciences Seed Fund in prior rounds, with Blue Horizon focusing on protein alternatives and food tech having invested in over 70 companies. |
| Jun 2020 | Series B | Temasek (lead); Tekfen Ventures; Skyviews Life Science; Future Planet Capital; Genoa Ventures; Emerald Technology Ventures; Aliment Capital; Bits x Bites; Sumitomo Corporation Europe Limited; UK Innovation & Science Seed Fund; Five Seasons Ventures; Agronomics | $29M | $967M | Tropic Biosciences UK Ltd., a Norwich-based agribiotech company, develops high-performance varieties of tropical crops like bananas and coffee using proprietary gene-editing (GEiGs platform) and RNAi technologies to enhance disease resistance, shelf life, reduced caffeine, and climate resilience. The company focuses on crops with massive market impact, targeting bananas, coffee (combined $50B+ annual value, 500M+ jobs), and expanding to rice (3.5B people reliant for 20%+ daily calories). It licenses its computational platform to clients across agriculture segments, including livestock. On March 31, 2020 (announced around April 6, 2020), Tropic closed a $28.5M Series B equity round led by Temasek Holdings, with participation from new investors Sumitomo Corporation Europe Limited, Genoa Ventures, Skyviews Life Science, Agronomics, and existing ones like Five Seasons Ventures, Pontifax AgTech, Emerald Technology Ventures, Tekfen Ventures, Bits x Bites, UK Innovation & Science Seed Fund (managed by Midven), and Aliment Capital. The round involved 2,415,254 Series B convertible preferred shares priced at $11.8 each, implying a post-money valuation of approximately $967M; Agronomics acquired 254,237 shares for $3M (2.95% post-conversion stake). Total funding to date reached $40M, following a $10M Series A in June 2018 co-led by Pontifax and Five Seasons. Proceeds fund commercialization of the GEiGs platform, field trials for banana varieties in Latin America/Southeast Asia, rice trait development for climate resistance, and scaling for broader crop applications. The round, the largest UK AgriTech raise at the time, proceeded unaffected by early COVID-19 due to pre-set Temasek terms, underscoring investor confidence in Tropic's execution, key commercial agreements, and role in global food security. |
| Jun 2018 | Series A | Aliment Capital (lead); Five Seasons Ventures (lead); Tekfen Ventures; Future Planet Capital; Emerald Technology Ventures; Bits x Bites; UK Innovation & Science Seed Fund | $10M | - | Tropic Biosciences, a UK-based agricultural biotechnology company founded in late 2016 at Norwich Research Park, develops high-performance varieties of tropical crops like bananas, coffee, and rice using gene-editing technologies including CRISPR and its proprietary GEiGS platform. The company targets traits that enhance yields, disease resistance, and sustainability to benefit growers, processors, and consumers in markets exceeding $50 billion. On June 13, 2018, Tropic Biosciences raised a $10 million oversubscribed Series A funding round co-led by Pontifax AgTech and Five Seasons Ventures, with participation from Tekfen Ventures, Emerald Technology Ventures, Bits x Bites, and the UK Innovation & Science Seed Fund. This followed a $1.4 million seed round in 2017, bringing total equity to around $11.4 million at that point. The team of 17 included experts with prior Monsanto-acquired startup experience. Proceeds supported development of disease-resistant banana and coffee varieties, field trials, and commercialization efforts. Investors highlighted Tropic's leadership in tropical crop gene editing and key commercial agreements post-GEiGS launch in 2019. The round positioned Tropic for growth in underserved massive markets with potential partners like Dole and Nestle. |
Who has invested in Tropic Biosciences?
25 investors have backed Tropic Biosciences across its funding rounds, including Five Seasons Ventures, Aliment Capital, Tekfen Ventures, Temasek, Future Planet Capital and UK Innovation & Science Seed Fund.
Lead investors include Corteva Catalyst, Forbion Capital Partners, Blue Horizon Corporation, Temasek, Aliment Capital and 1 other investor.
Tropic Biosciences Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Participant | Jun 2018 | ||
| 3 | Lead | Jun 2018 | ||
| 3 | Lead | Jun 2018 | ||
| 2 | Lead | Jun 2020 | ||
| 2 | Participant | Jun 2020 | ||
| 2 | Participant | Jun 2018 | ||
| 2 | Participant | Jun 2020 | ||
| 2 | Participant | Jul 2022 | ||
| 2 | Participant | Jun 2018 | ||
| 2 | Participant | Jun 2018 | ||
| 2 | Participant | Jun 2018 | ||
| 1 | Participant | Jul 2022 | ||
| 1 | Participant | Mar 2026 | ||
This data is available for Pro users. Sign up to see all 25 Tropic Biosciences investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Tropic Biosciences
Tropic Biosciences has acquired 1 company to date.
Last acquisition by Tropic Biosciences was on June 21st 2026. Tropic Biosciences acquired Rahan Meristem for $20M.
Latest Acquisitions by Tropic Biosciences
| Description | Rahan Meristem is a plant biotech company that multiplies and develops crop varieties for global distribution, with production sites in several nations. |
| HQ Country | |
| HQ City | Afikim |
| Deal Date | 21 Jun 2026 |
| Valuation | $20M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Tropic Biosciences acquisitions and their M&A valuation multiples. Start Free Trial | |
Tropic Biosciences Competitors
Tropic Biosciences competitors include listed companies like Elders, AGT Food and Ingredients and Okomu Oil Palm Company, and private ones like Fruitist, Infarm and Semios.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $2.3B | $119M | $969M | 0.6x | ||
| Publicly listed | $59M | $56M | $994M | 0.5x | ||
| Private | - | - | $1B | - | ||
| Private | - | - | $1B | - | ||
| Private | $37M | - | $1B | 27.0x | ||
| Publicly listed | $149M | $88M | $1B | 6.3x |
Tropic Biosciences Public Comps
Tropic Biosciences is still privately-owned, but its public comps include Elders, AGT Food and Ingredients, Okomu Oil Palm Company, 3tentos, Zad Holding, Cresud, Nufarm, Graincorp, AEP Plantations and NPK International.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $2.3B | $119M | 0.7x | 0.6x | 13.5x | 8.1x | |||
| $59M | $56M | 18.1x | 0.5x | 18.9x | 7.5x | |||
| $149M | $88M | 6.8x | 6.3x | 11.6x | - | |||
| $3.2B | $233M | 0.5x | 0.5x | 7.5x | 7.8x | |||
| $348M | $82M | 2.6x | - | 11.1x | - | |||
| $912M | $428M | 3.2x | 3.1x | 6.9x | 8.9x | |||
| $2.4B | $101M | 0.8x | 0.8x | 19.3x | 7.2x | |||
| $5.2B | $179M | 0.4x | 0.5x | 12.2x | 13.8x | |||
This data is available for Pro users. Sign up to see all Tropic Biosciences competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Tropic Biosciences
| When was Tropic Biosciences founded? | Tropic Biosciences was founded in 2016. |
| Where is Tropic Biosciences headquartered? | Tropic Biosciences is headquartered in London, United Kingdom. |
| Is Tropic Biosciences publicly listed? | No, Tropic Biosciences is a private, VC-backed company. |
| What is Tropic Biosciences' valuation? | Tropic Biosciences was last valued at $967M in its Series B in June 2020. |
| How much funding has Tropic Biosciences raised? | Tropic Biosciences has raised $179M across 4 funding rounds. |
| What was Tropic Biosciences' last funding round? | Tropic Biosciences' last funding round was a $105M Series C in March 2026, led by Corteva Catalyst and Forbion Capital Partners. |
| Who are Tropic Biosciences' investors? | Tropic Biosciences' investors include Tekfen Ventures, Aliment Capital, Five Seasons Ventures, Temasek, Skyviews Life Science, Future Planet Capital, Genoa Ventures, Sucden Ventures, Emerald Technology Ventures, Bits x Bites and 15 others. |
| Which companies are comparable to Tropic Biosciences? | Companies comparable to Tropic Biosciences include Elders, AGT Food and Ingredients, Fruitist, Infarm, Semios and Okomu Oil Palm Company. |
| How many companies has Tropic Biosciences acquired? | Tropic Biosciences has acquired 1 company, including Rahan Meristem. |
| What was the largest acquisition by Tropic Biosciences? | The $20M acquisition of Rahan Meristem in June 2026 is the largest acquisition Tropic Biosciences has made to date. |
See companies similar to Tropic Biosciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




